(Bloomberg) — Eli Lilly agreed to buy Waltham-based gut-drug maker Morphic Holding Inc. for about $3.2 billion, plowing some ...
Federal filings showed no companies other than Lilly made an offer to buy Morphic, while Novartis executives said they’re still waiting for more data on pelabresib.
Eli Lilly says it will acquire a Waltham-based drug company that's working on a treatment for inflammatory bowel disease.
Eli Lilly LLY-0.60%decrease; red down pointing triangle has agreed to buy biopharmaceutical company Morphic Holding MORF 0.02%increase; green up pointing triangle for $3.2 billion in a deal ...
Eli Lilly has won approval from Chinese regulators to sell its weight-loss treatment tirzepatide in the country, the company ...
Eli Lilly (LLY) offers to acquire Morphic Therapeutics for $3.2 billion. Pfizer (PFE) selects a once-daily formulation of danuglipron for further development as a weight loss pill. Is Eli ...
This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order ...